The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Rachel Schiff, H. Shelton Brown et al.|British Journal of Cancer|2018Cited by 65
Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapyAgostina Nardone, Rachel Schiff, Hazel M. Weir et al.|Cancer Research|2017Cited by 0